{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Protara Therapeutics, Inc.
Is Protara Therapeutics, Inc. technically bullish or bearish?
As of June 18, 2025, Protara Therapeutics, Inc. is in a bearish trend, supported by weekly MACD, Bollinger Bands, and daily moving averages, despite some divergence indicated by the KST.
Who are in the management team of Protara Therapeutics, Inc.?
As of March 2022, the management team of Protara Therapeutics, Inc. includes Chairman Luke Beshar, CEO Jesse Shefferman, and several directors: Barry Flannelly, Roger Garceau, Richard Levy, Gregory Sargen, and Michael Solomon. They oversee the company's strategic direction and operations.
What does Protara Therapeutics, Inc. do?
Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for rare and specialty diseases. As of March 2025, it has a market cap of $118.06 million and reported a net profit loss of $12 million.
How big is Protara Therapeutics, Inc.?
As of Jun 18, Protara Therapeutics, Inc. has a market capitalization of 118.06 million, with net sales of 0.00 million and a net profit of -45.41 million over the latest four quarters. The company reported shareholder's funds of 167.13 million and total assets of 181.45 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
